About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.

Cultivated Autologous Oral Mucosal Epithelial Transplantation

Clinicaltrials.gov identifier NCT03943797

Recruitment Status Recruiting

First Posted May 9, 2019

Last update posted August 13, 2020

Study Description

Brief summary:

Earlier protocol for cultivated oral mucosal epithelial transplantation (COMET) requires trypsin/EDTA to isolate epithelial cells from tissue, and uses murine 3T3 cells as feeder cells, which results in biosafety concern. This study uses collagenase instead of trypsin/EDTA to isolate epithelial cells, and does not use 3T3 cells co-culture, so as to make an animal ingredient-free cell culture product. The purpose of the study is to evaluate the feasibility of the new protocol of COMET in clinical use.

  • Condition or Disease:Limbal Stem Cell Deficiency
  • Intervention/Treatment: Biological: Cultivated oral mucosal epithelial cell transplantation
  • Phase: Phase 1
Detailed Description

When corneal epithelial stem cells are destroyed by severe trauma such as burn or autoimmune diseases, poor regeneration of corneal epithelium, persistent inflammatory reaction, neovascular ingrowth, and conjunctivalization may ensue, and seriously reduce the vision. In treating the diseased eye, when the other eye is healthy, limbal tissue containing corneal epithelial stem cells can be harvested for direct tissue transplantation, or ex vivo cultivation and expansion for several days before transplantation. For patients with bilaterally damaged eyes, rejection rate in non-HLA matched allograft limbal stem cell transplantation is very high, in addition, adverse reaction to long-term immunosuppressive therapy may be life-threatening. Therefore, in 2004 Japanese researchers first proposed a novel technique to treat ocular surface diseases using cultivated autologous oral mucosal epithelial transplantation (COMET). From 2006 to 2009, investigators have also conducted a Phase I clinical trial approved by Taiwan FDA. In that Phase I trial, investigators have demonstrated efficacy of such cell therapy in promoting wound healing in patients with severe ocular surface burns (Ma DHK et al. Eye 2009; 23: 1442- 1450). Investigators have also identify long-term persistence of transplanted oral mucosal epithelial cells in the cornea (Chen HCJ et al. IOVS 2009;50:4660-4668), justifying this innovative surgical procedure as an effective alternative treatment modality. However, in previous protocol, animal products such as fetal calf serum and 3T3 cell culture were used, raising the biosafety concern. For this, recently investigators have developed an animal ingredient-free cell culture protocol, and our protocol can meet the GTP standards, and has obtained the accreditation by Taiwan FDA and affiliated institutes. Therefore, the focus of current Phase Ib trial is to confirm the feasibility and safety of following items: 1. To produce cell culture product not containing animal ingredient, so as to avoid zoonoses. The oral mucosal epithelial cells thus cultured are used for treating ocular surface diseases with limbal stem cell deficiency. 2. To reduce recurrence of corneal neovascularization after COMET, Bevacizumab (Avastin) is injected locally, so as to improve corneal transparency and visual acuity.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 8 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Cultivated Autologous Oral Mucosal Epithelial Transplantation for the Treatment of Ocular Surface Diseases: A Clinical Study
  • Actual Study Start Date: March 2016
  • Estimated Primary Completion Date: December 2024
  • Estimated Study Completion Date: December 2024
Arms and interventions
Arm Intervention/treatment
Experimental: Cultivated oral mucosal epithelial cell transplantation
Cell therapy for treating severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cells.
Biological: Cultivated oral mucosal epithelial cell transplantation
Cultivated oral mucosal epithelial cell transplantation (COMET) will be used to treat severe limbal stem cell deficiency so as to restore the integrity of corneal surface
Outcome Measures
  • Primary Outcome Measures: 1. The proportion of study specific AE [ Time Frame: 12 months ]
    The tolerance and safety
Eligibility Criteria
  • Ages Eligible for Study: 18 to 80 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

- Severe corneal epithelial deficiency

- Having favorable prognosis potential

- Normal of the intraocular pressure

- Normal of the light perception for the optic nerve

- No retinal diseases for the inflicted eyes

- No severe dry eye

Exclusion Criteria:

- Having unfavorable prognosis potential

- Severe systemic disorders

- Unable to use daily vision

- Mentally retarded to execute permit on surgery

- Pregnant woman

Contacts and Locations
Contacts

Contact: David Hui-Kang Ma, MD, PhD 03-328-1200 ext 7840 davidhkma@yahoo.com

Contact: Zheng Hua Huang, MSc 03-328-1200 ext 7840 a513115@yahoo.com.tw

Locations

Taiwan
Core Laboratory for Cell Therapy, Veterans General Hospital
Taipei

Sponsors and Collaborators

Chang Gung Memorial Hospital

Investigators

Principal Investigator: David Hui-Kang Ma, MD, PhD Chang Gung Memorial Hospital

More Information